Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-04-14

Clinical Trial Update: A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate spesolimab in people with Pyoderma Gangrenosum is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPESOLIMAB (BI655130)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pyoderma Gangrenosum | Phase 3 | Status: RECRUITING